Compare Regeneron Pharmaceuticals Inc (REGN) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs UnitedHealth Group Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while UnitedHealth Group Inc trades at $379.3 (market cap $332.96B). The key difference: UnitedHealth Group Inc is far larger — about 4.4× Regeneron Pharmaceuticals Inc's market cap, and UnitedHealth Group Inc pays the higher dividend (2.5%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and UnitedHealth Group Inc for 97 Days on average.
| REGN | UNH | |
|---|---|---|
Market Cap | $76.14B | $332.96B |
Volume | 500,239 | 7,273,749 |
Sector | Health | Health |
52-Week High | $852.03 | $436.35 |
52-Week Low | $557.73 | $259.02 |
Typical Hold Time | 107 Days | 97 Days |
Enterprise Value | $70.85B | $374.82B |
Dividend Yield | 0.51% | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
UnitedHealth Group (UNH) trades at $370.95, down 1.34% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $6.38 versus $4.91 expected, and raised full-year guidance. Revenue for 2025 reached $447.57 billion, though net income margin declined to 2.69%. Analyst consensus remains strongly bullish with an 82.69% buy rating and a $470.11 price target, suggesting significant upside from current levels.
UNH presents a compelling investment case driven by earnings beats, raised 2026 outlook, and strategic initiatives like AI investment in Optum. Key risks include regulatory pressures in healthcare, volatility from Medicare Advantage plan changes, and margin compression. The stock's valuation at a P/E of 23.84 appears reasonable given growth prospects, but investors should weigh execution risks against the positive analyst sentiment and institutional backing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
